REHOVOT, Israel, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, announced today that Assaf Kacen, Chief Operating Officer, will participate at the Piper Jaffray Global Agriculture Symposium taking place in Minneapolis, Minnesota, August 2, 2016.
Mr. Kacen will take part at the Gene Editing panel which will take place on Tuesday, August 2, at 2:00 pm. He will discuss the potential of genome editing to significantly impact traditional breeding pipelines, and the potential effect of the disruptive technology on the expansion of Evogene's business offering.
Investors or potential partners attending the conference, who wish to meet with Mr. Kacen, may contact Evogene’s Investor Relations team at firstname.lastname@example.org.
About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at email@example.com.
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Eyal Leibovitz, CFO E: IR@evogene.com T: +972 8931 1900